Want to join the conversation?
$ENTA said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for $ABBV's investigational chronic hepatitis C virus (HCV) regimen. Glecaprevir (GLE) is $ENTA's second protease inhibitor being developed through its collaboration with $ABBV.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?